Literature DB >> 12163786

Influence on outcome of ventilator-associated pneumonia in multiple trauma patients with head trauma treated with selected digestive decontamination.

Marc Leone1, Aurélie Bourgoin, Elsa Giuly, François Antonini, Myriam Dubuc, Xavier Viviand, Jacques Albanèse, Claude Martin.   

Abstract

OBJECTIVE: Ventilator-associated pneumonia is said to be associated with an increased mortality or a prolonged intensive care unit stay. In multiple trauma, the use of selective digestive decontamination has been reported to decrease morbidity and mortality associated with pneumonia. We performed a study to evaluate the attributable morbidity and mortality of ventilator-associated pneumonia in multiple trauma patients with head trauma treated with selective digestive decontamination.
DESIGN: Prospective, matched-paired, case-control study.
SETTING: Intensive care unit at a tertiary university hospital. PATIENTS: During a 6-yr period, 324 consecutive multiple trauma patients with head trauma requiring mechanical ventilation for >48 hrs were prospectively followed for the development of VAP. Case-control matching criteria were as follows: 1) age difference within 5 yrs, 2) Glasgow coma scale within five categories, 3) injury severity score within 5 points, 4) APACHE II score within 5 points, 5) ventilation of control patients for at least as long as the cases. The selective digestive decontamination regimen was used in all patients (cases and controls): polymixin E, gentamicin, and amphotericin B. Systemic cefazolin (1 g three times a day) was given for the first 3 days of intensive care unit stay.
MEASUREMENTS AND MAIN RESULTS: Analysis was performed on 58 pairs that were matched with 100% of success The most common isolates recovered were Staphylococcus aureus (39%) and Haemophilus influenzae (22%). High-risk pathogens were rarely isolated: Pseudomonas aeruginosa (5.1%), Acinetobacter species (8.6%), and methicillin-resistant S. aureus (6.7%). The duration of mechanical ventilation and intensive care unit stay were increased in case patients (11.6 +/- 1.7 and 22.7 +/- 2.9 days, respectively) compared with control patients (9.4 +/- 1.3 and 16.8 +/- 2.9 days, respectively; p <.0006). Mortality was similar in both case (17%) and control (24%) patients.
CONCLUSION: Ventilator-associated pneumonia did not seem to increase mortality of multiple trauma patients with head trauma who received selective digestive decontamination. Whether or not this conclusion applied to trauma patients not receiving selective digestive decontamination should be evaluated in further studies.

Entities:  

Mesh:

Year:  2002        PMID: 12163786     DOI: 10.1097/00003246-200208000-00011

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  10 in total

1.  Risk factors for late-onset ventilator-associated pneumonia in trauma patients receiving selective digestive decontamination.

Authors:  Marc Leone; Stéphane Delliaux; Aurélie Bourgoin; Jacques Albanèse; Franck Garnier; Ioana Boyadjiev; Francois Antonini; Claude Martin
Journal:  Intensive Care Med       Date:  2004-12-02       Impact factor: 17.440

2.  Hospital-acquired pneumonia is an independent predictor of poor global outcome in severe traumatic brain injury up to 5 years after discharge.

Authors:  Matthew Ryan Kesinger; Raj G Kumar; Amy K Wagner; Juan Carlos Puyana; Andrew P Peitzman; Timothy R Billiar; Jason L Sperry
Journal:  J Trauma Acute Care Surg       Date:  2015-02       Impact factor: 3.313

3.  Ventilator-associated pneumonia in severe traumatic brain injury.

Authors:  David A Zygun; Danny J Zuege; Paul J E Boiteau; Kevin B Laupland; Elizabeth A Henderson; John B Kortbeek; Christopher J Doig
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

4.  Effects of hospital-acquired pneumonia on long-term recovery and hospital resource utilization following moderate to severe traumatic brain injury.

Authors:  Raj G Kumar; Matthew R Kesinger; Shannon B Juengst; Maria M Brooks; Anthony Fabio; Kristen Dams-O'Connor; Mary Jo Pugh; Jason L Sperry; Amy K Wagner
Journal:  J Trauma Acute Care Surg       Date:  2020-04       Impact factor: 3.697

5.  The effect of sedation and/or analgesia as rescue treatment during noninvasive positive pressure ventilation in the patients with Interface intolerance after Extubation.

Authors:  Yue-Nan Ni; Ting Wang; He Yu; Bin-Miao Liang; Zong-An Liang
Journal:  BMC Pulm Med       Date:  2017-09-15       Impact factor: 3.317

Review 6.  Incidence, Risk Factors, and Outcomes of Ventilator-Associated Pneumonia in Traumatic Brain Injury: A Meta-analysis.

Authors:  Yating Li; Chenxia Liu; Wei Xiao; Tiantian Song; Shuhui Wang
Journal:  Neurocrit Care       Date:  2020-02       Impact factor: 3.210

7.  Risk factors and outcomes for prolonged versus brief fever: a prospective cohort study.

Authors:  Philippe Seguin; Antoine Roquilly; Olivier Mimoz; Pascale Le Maguet; Karim Asehnoune; Sébastien Biederman; Elsa Carise; Yannick Malledant
Journal:  Crit Care       Date:  2012-08-13       Impact factor: 9.097

Review 8.  Risks associated with magnetic resonance imaging and cervical collar in comatose, blunt trauma patients with negative comprehensive cervical spine computed tomography and no apparent spinal deficit.

Authors:  C Michael Dunham; Brian P Brocker; B David Collier; David J Gemmel
Journal:  Crit Care       Date:  2008-07-14       Impact factor: 9.097

9.  Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study.

Authors:  Saad Nseir; Raphaël Favory; Elsa Jozefowicz; Franck Decamps; Florent Dewavrin; Guillaume Brunin; Christophe Di Pompeo; Daniel Mathieu; Alain Durocher
Journal:  Crit Care       Date:  2008-05-02       Impact factor: 9.097

10.  Impact of ventilator associated pneumonia on outcome in patients with chronic obstructive pulmonary disease exacerbation.

Authors:  Vijay Hadda; Gopi Chand Khilnani; Gajendra Dubey; Rajkanna Nallan; Guresh Kumar; Randeep Guleria
Journal:  Lung India       Date:  2014-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.